🚀 VC round data is live in beta, check it out!
CROSSJECT Valuation Multiples
Discover revenue and EBITDA valuation multiples for CROSSJECT and similar public comparables like Treace Medical Concepts, Onyx Healthcare, Viromed Medical, Hyperfine and more.
CROSSJECT Overview
About CROSSJECT
CROSSJECT manufactures and markets needle-free drug self-injection system.
Founded
2002
HQ
Employees
54
Website
Sectors
Financials (LTM)
EV
$142M
CROSSJECT Financials
CROSSJECT reported last 12-month revenue of $19M and EBITDA of $3M.
In the same LTM period, CROSSJECT generated $3M in EBITDA and had net loss of ($6M).
Revenue (LTM)
CROSSJECT P&L
In the most recent fiscal year, CROSSJECT reported revenue of $9M and EBITDA of ($7M).
CROSSJECT expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $19M | XXX | $9M | XXX | XXX | XXX |
| Gross Profit | — | XXX | ($11M) | XXX | XXX | XXX |
| Gross Margin | — | XXX | (133%) | XXX | XXX | XXX |
| EBITDA | $3M | XXX | ($7M) | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | (81%) | XXX | XXX | XXX |
| EBIT Margin | (25%) | XXX | (151%) | XXX | XXX | XXX |
| Net Profit | ($6M) | XXX | ($12M) | XXX | XXX | XXX |
| Net Margin | (30%) | XXX | (137%) | XXX | XXX | XXX |
| Net Debt | — | — | $17M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
CROSSJECT Stock Performance
CROSSJECT has current market cap of $125M, and enterprise value of $142M.
Market Cap Evolution
CROSSJECT's stock price is $2.36.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $142M | $125M | 1.4% | XXX | XXX | XXX | $-0.22 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCROSSJECT Valuation Multiples
CROSSJECT trades at 7.6x EV/Revenue multiple, and 52.1x EV/EBITDA.
EV / Revenue (LTM)
CROSSJECT Financial Valuation Multiples
As of April 20, 2026, CROSSJECT has market cap of $125M and EV of $142M.
Equity research analysts estimate CROSSJECT's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CROSSJECT has a P/E ratio of (22.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $125M | XXX | $125M | XXX | XXX | XXX |
| EV (current) | $142M | XXX | $142M | XXX | XXX | XXX |
| EV/Revenue | 7.6x | XXX | 16.6x | XXX | XXX | XXX |
| EV/EBITDA | 52.1x | XXX | (20.5x) | XXX | XXX | XXX |
| EV/EBIT | (30.0x) | XXX | (10.9x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (12.5x) | XXX | XXX | XXX |
| P/E | (22.3x) | XXX | (10.6x) | XXX | XXX | XXX |
| EV/FCF | (17.7x) | XXX | (11.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified CROSSJECT Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
CROSSJECT Margins & Growth Rates
CROSSJECT's revenue in the last 12 month grew by 141%.
CROSSJECT's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.0M for the same period.
CROSSJECT Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 141% | XXX | 396% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | (81%) | XXX | XXX | XXX |
| EBITDA Growth | 985% | XXX | (508%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 46% | XXX | 144% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 26% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
CROSSJECT Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| CROSSJECT | XXX | XXX | XXX | XXX | XXX | XXX |
| Treace Medical Concepts | XXX | XXX | XXX | XXX | XXX | XXX |
| Onyx Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Viromed Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Hyperfine | XXX | XXX | XXX | XXX | XXX | XXX |
| Edap TMS | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CROSSJECT M&A Activity
CROSSJECT acquired XXX companies to date.
Last acquisition by CROSSJECT was on XXXXXXXX, XXXXX. CROSSJECT acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by CROSSJECT
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCROSSJECT Investment Activity
CROSSJECT invested in XXX companies to date.
CROSSJECT made its latest investment on XXXXXXXX, XXXXX. CROSSJECT invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by CROSSJECT
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout CROSSJECT
| When was CROSSJECT founded? | CROSSJECT was founded in 2002. |
| Where is CROSSJECT headquartered? | CROSSJECT is headquartered in France. |
| How many employees does CROSSJECT have? | As of today, CROSSJECT has over 54 employees. |
| Is CROSSJECT publicly listed? | Yes, CROSSJECT is a public company listed on Euronext Paris. |
| What is the stock symbol of CROSSJECT? | CROSSJECT trades under ALCJ ticker. |
| When did CROSSJECT go public? | CROSSJECT went public in 2014. |
| Who are competitors of CROSSJECT? | CROSSJECT main competitors are Treace Medical Concepts, Onyx Healthcare, Viromed Medical, Hyperfine. |
| What is the current market cap of CROSSJECT? | CROSSJECT's current market cap is $125M. |
| What is the current revenue of CROSSJECT? | CROSSJECT's last 12 months revenue is $19M. |
| What is the current revenue growth of CROSSJECT? | CROSSJECT revenue growth (NTM/LTM) is 141%. |
| What is the current EV/Revenue multiple of CROSSJECT? | Current revenue multiple of CROSSJECT is 7.6x. |
| Is CROSSJECT profitable? | Yes, CROSSJECT is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of CROSSJECT? | CROSSJECT's last 12 months EBITDA is $3M. |
| What is CROSSJECT's EBITDA margin? | CROSSJECT's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of CROSSJECT? | Current EBITDA multiple of CROSSJECT is 52.1x. |
| What is the current FCF of CROSSJECT? | CROSSJECT's last 12 months FCF is ($8M). |
| What is CROSSJECT's FCF margin? | CROSSJECT's last 12 months FCF margin is (43%). |
| What is the current EV/FCF multiple of CROSSJECT? | Current FCF multiple of CROSSJECT is (17.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.